Government proposes immediate suspension of manufacturing licences of substandard drugs

A medicine described as Not of Standard Quality, or NSQ, has failed a prescribed quality requirement identified through regulatory testing. The finding signals that the product does not meet the standard expected for a medicine, although the article focuses on specified critical parameters rather than defining every possible NSQ failure.

For example, a Government Analyst may report that a batch has an assay problem, dissolves improperly, contains unacceptable related substances or impurities, or is not sterile. After such a report, the proposed rules would allow the relevant licensing authority to suspend the manufacturing licence immediately.

The article says this change is intended to protect patients and public health. Under current rules, action normally follows a show-cause notice, creating a possible delay. The draft would keep suspension in place until the manufacturer completes root cause analysis, implements corrective and preventive action, and satisfies verification by the licensing authority.

The proposed change would let the Central Licensing Approving Authority or State Licensing Authority immediately suspend a manufacturing licence after receiving a Government Analyst’s report declaring a medicine NSQ on specified critical parameters. This removes the possible gap before action under the existing procedure.

For example, if a report identifies a failure involving assay, dissolution, related substances, impurities or sterility, the relevant authority could suspend the licence without waiting for the usual sequence to begin. The manufacturer would then need to conduct an effective root cause analysis and implement appropriate Corrective and Preventive Action, or CAPA.

The suspension would not automatically end when the manufacturer claims the problem is fixed. The licensing authority must be satisfied that corrective and preventive measures were implemented and must verify them before revoking the suspension. The draft amendments are open to public objections and suggestions for 30 days.

The proposed immediate-suspension rule applies when a medicine is declared NSQ for assay, dissolution, related substances, impurities or sterility. These are the specific critical quality parameters named in the draft mechanism. The article describes them as important for determining medicine quality.

Assay concerns whether the medicine contains the required amount of its active ingredient. Dissolution concerns how the medicine releases that ingredient for use. Related substances and impurities indicate unwanted chemical components. Sterility testing checks whether products required to be sterile meet that requirement. A failure in any listed area could trigger immediate suspension.

The proposed action is intended to minimise potential patient risks. Once the Government Analyst’s report is received, the Central Licensing Approving Authority or State Licensing Authority could suspend the manufacturing licence. It would remain suspended until corrective measures are implemented and verified.

The consultation period lasts 30 days. Members of the public and stakeholders can submit objections and suggestions during that period on the proposed amendments to the Drugs Rules, 1945.

The clock does not simply begin with the government’s announcement. The article specifies that the 30-day period starts from the date copies of the Gazette of India containing the draft rules are made available to the public. This gives interested parties a defined window to respond to the proposal.

The consultation is part of the rule-making process, not the final enforcement stage. The Ministry has notified the draft for public consultation after earlier discussions and recommendations by the Drugs Consultative Committee and Drugs Technical Advisory Board. The article does not state when the final amendments will be issued or when any new suspension provision would take effect.

When a substandard medicine remains in circulation during regulatory delays, patients may continue to encounter a product that has failed a critical quality requirement. The government says this can pose potential risks to public health, especially while the medicine remains available through the distribution chain.

The article gives a regulatory example rather than describing a particular patient case. Under existing rules, suspension or cancellation normally follows prescribed steps, including a show-cause notice. The time between an NSQ declaration and regulatory action may allow continued manufacture or distribution. That delay can make it harder to identify and remove affected medicines effectively.

The proposed immediate suspension is designed to reduce this gap. It would stop the manufacturing licence from continuing after specified NSQ findings, while corrective work is required. The article says the approach should minimise potential patient risks and facilitate timely action against substandard medicines.

The proposed Form 13 arrangement would send the Government Analyst’s report to the Drugs Controller General of India, the concerned State or Union Territory Licensing Authority, and the manufacturer and marketer of the drug. This is intended to ensure that the finding reaches all relevant authorities and businesses quickly.

The Central Licensing Approving Authority or the State Licensing Authority could immediately suspend the manufacturing licence after receiving a report declaring the medicine NSQ on a listed critical parameter. The manufacturer must then investigate the root cause and implement appropriate Corrective and Preventive Action, or CAPA.

Restoration would require more than a written assurance. The licensing authority must be satisfied that the necessary corrective and preventive measures have been implemented, and must verify them before revoking the suspension. The proposed information flow is intended to improve coordination, accountability and timely regulatory action.

Assay testing checks whether a medicine contains the expected amount of its active ingredient, so it addresses strength. Dissolution testing examines how the medicine releases its contents. Related-substance and impurity analysis looks for unwanted chemical components. Sterility testing checks whether a product meets sterility requirements. Together, these tests examine important aspects of medicine quality.

For example, a failed assay could indicate an incorrect amount of active ingredient, while a dissolution failure could show that the medicine does not release as expected. An impurity finding could identify unwanted substances, and a sterility failure could indicate that a product intended to be sterile does not meet that requirement.

The article identifies all five as critical parameters for regulatory action. A Government Analyst’s report finding failure in one could lead to immediate licence suspension under the proposal. The manufacturer would then need root cause analysis and CAPA before restoration is considered.